Dysregulation of microRNAs and Centromere Protein Genes in Prostate Cancer and Metastatic Progression

OBJECTIVE: Accurate prediction of disease progression and metastatic potential remains a major challenge in prostate cancer management. This study aimed to evaluate the expression profiles of selected microRNAs (miRNAs) and cell cycle-related genes as centromere protein genes (CENPs) in prostate cancer and to explore their potential clinical relevance in distinguishing metastatic disease. METHODS: Formalin-fixed paraffin-embedded prostate tissue samples from patients with benign prostatic hyperplasia, localized prostate cancer, and metastatic prostate cancer were analyzed. Quantitative real-time polymerase chain reaction (PCR) (qRTPCR) was used to assess the expression of miRNAs targeted CENPs as well as CENPA, CENPC, HJURP, and AURKB. Expression patterns were further validated in the metastatic prostate cancer cell line PC3. Relative expression levels were calculated using the 2-ΔΔCt (cycle threshold) method. RESULTS: Expression analysis of selected miRNAs revealed a significant upregulation of hsa-miR-4755-5p in the metastatic PCa (P = .027), despite no significant differences in fold change. Additionally, hsa-miR-5680 showed a significantly higher fold change in the metastatic group compared to controls (P = .034). Although not statistically significant (P > .05), hsa-miR-5688, hsa-miR-20a-5p, and hsa-miR-4500 demonstrated a consistent trend toward downregulation, as indicated by lower ΔΔCt values in both PCa and metastatic groups relative to controls. In PCa cell line CENPA, CENPC,and HJURP expression levels increased over time, whereas AURKB was downregulated. CONCLUSION: The findings indicate that combined dysregulation of specific microRNAs and centromere-associated genes characterizes metastatic prostate cancer. This molecular signature may provide clinically relevant information for risk stratification and warrants further investigation as a potential adjunct to conventional prognostic markers in prostate cancer. Cite this article as: Somuncu MN, Karalezli I, Göger YE, et al. Dysregulation of microRNAs and centromere protein genes in prostate cancer and metastatic progression. Urol Res Pract., 52, 0143, doi:10.5152/tud.2026.26143.

Authors

Institutions

Publication Details

Journal
Urology Research and Practice
Published
2026-04-02
DOI
https://doi.org/10.5152/tud.2026.26143
Primary Topic
MicroRNA in disease regulation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dysregulation of microRNAs and Centromere Protein Genes in Prostate Cancer and Metastatic Progression

Mustafa Cihat Avunduk, Makbule Nihan Somuncu, Mahmut Selman Yıldırım, Ayşe Gül Zamani et al.
Urology Research and Practice
MicroRNA in disease regulation
article

Dysregulation of microRNAs and Centromere Protein Genes in Prostate Cancer and Metastatic Progression

Mustafa Cihat Avunduk, Makbule Nihan Somuncu, Mahmut Selman Yıldırım, Ayşe Gül Zamani, Asuman DEVECİ, Giray Karalezli, İlknur Karalezli
article en

Abstract

OBJECTIVE: Accurate prediction of disease progression and metastatic potential remains a major challenge in prostate cancer management. This study aimed to evaluate the expression profiles of selected microRNAs (miRNAs) and cell cycle-related genes as centromere protein genes (CENPs) in prostate cancer and to explore their potential clinical relevance in distinguishing metastatic disease. METHODS: Formalin-fixed paraffin-embedded prostate tissue samples from patients with benign prostatic hyperplasia, localized prostate cancer, and metastatic prostate cancer were analyzed. Quantitative real-time polymerase chain reaction (PCR) (qRTPCR) was used to assess the expression of miRNAs targeted CENPs as well as CENPA, CENPC, HJURP, and AURKB. Expression patterns were further validated in the metastatic prostate cancer cell line PC3. Relative expression levels were calculated using the 2-ΔΔCt (cycle threshold) method. RESULTS: Expression analysis of selected miRNAs revealed a significant upregulation of hsa-miR-4755-5p in the metastatic PCa (P = .027), despite no significant differences in fold change. Additionally, hsa-miR-5680 showed a significantly higher fold change in the metastatic group compared to controls (P = .034). Although not statistically significant (P > .05), hsa-miR-5688, hsa-miR-20a-5p, and hsa-miR-4500 demonstrated a consistent trend toward downregulation, as indicated by lower ΔΔCt values in both PCa and metastatic groups relative to controls. In PCa cell line CENPA, CENPC,and HJURP expression levels increased over time, whereas AURKB was downregulated. CONCLUSION: The findings indicate that combined dysregulation of specific microRNAs and centromere-associated genes characterizes metastatic prostate cancer. This molecular signature may provide clinically relevant information for risk stratification and warrants further investigation as a potential adjunct to conventional prognostic markers in prostate cancer. Cite this article as: Somuncu MN, Karalezli I, Göger YE, et al. Dysregulation of microRNAs and centromere protein genes in prostate cancer and metastatic progression. Urol Res Pract., 52, 0143, doi:10.5152/tud.2026.26143.

Urology Research and PracticeVol. 52
Sakarya University (TR), Selçuk University (TR), State Hospital (GB), Necmettin Erbakan University (TR)
Necmettin Erbakan Üniversitesi
Good health and well-being
Openalex Percentile: Top 25%
MicroRNA in disease regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.